bioAffinity Highlights CyPath Lung Case Study in Diagnostics

bioAffinity Technologies, Inc. ( (BIAF) ) has shared an update.

On February 19, 2026, bioAffinity Technologies released a clinical case study showing how its CyPath® Lung noninvasive diagnostic test guided treatment for a 79-year-old woman whose June 2025 low-dose CT scan revealed a suspicious spiculated lung nodule. The negative CyPath® Lung result indicated low likelihood of malignancy, leading clinicians to opt for surveillance rather than an invasive biopsy, and a follow-up CT in October 2025 showed the nodule had resolved with no pulmonary nodules present.

The case highlights CyPath® Lung’s potential to reduce the diagnostic burden in high-risk patients by providing objective risk stratification that can prevent unnecessary, risky and costly procedures while complementing imaging findings. With clinical data showing 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules under 2 centimeters, the study underscores the test’s role in supporting conservative management strategies and may strengthen bioAffinity’s positioning in the lung cancer diagnostics market.

The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage lung cancer and other lung diseases, as well as broad-spectrum cancer treatments. Its first product, CyPath® Lung, is a sputum-based Laboratory Developed Test that uses flow cytometry and AI to detect malignancy with reported high sensitivity, specificity and accuracy in high-risk patients with small indeterminate lung nodules.

CyPath® Lung is marketed through Precision Pathology Laboratory Services, a bioAffinity subsidiary, targeting high-risk individuals identified through lung cancer screening programs. The company’s technology incorporates a fluorescent porphyrin preferentially taken up by cancer and cancer-related cells, aiming to improve risk stratification and reduce unnecessary invasive procedures in lung cancer diagnostics.

Average Trading Volume: 106,709

Technical Sentiment Signal: Sell

Current Market Cap: $4.81M

See more data about BIAF stock on TipRanks’ Stock Analysis page.